Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.

doi:10.4049/jimmunol.2300308

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.

Journal of immunology (Baltimore, Md. : 1950) - 1 Jul 2024

Tanegashima Tokiyoshi, Shiota Masaki, Fujiyama Nobuhiro, Narita Shintaro, Habuchi Tomonori, Fukuchi Genshiro, Takamatsu Dai, Oda Yoshinao, Miyake Hideaki, Takahashi Masayuki, Oya Mototsugu, Tsuchiya Norihiko, Masumori Naoya, Matsuyama Hideyasu, Obara Wataru, Shinohara Nobuo, Fujimoto Kiyohide, Nozawa Masahiro, Ohba Kojiro, Ohyama Chikara, Hashine Katsuyoshi, Akamatsu Shusuke, Kamba Tomomi, Mita Koji, Gotoh Momokazu, Tatarano Shuichi, Fujisawa Masato, Tomita Yoshihiko, Mukai Shoichiro, Ito Keiichi, Tokunaga Shoji, Eto Masatoshi

Abstract excerpt

Immune checkpoint blockade therapies are widely used for cancer treatment, including advanced renal cell carcinoma (RCC). This study aimed to investigate the impact of zygosity in HLA genes and individual HLA genotypes on the efficacy of an anti-PD-1 Ab, nivolumab, in treating advanced RCC. Patient enrollment was conducted across 23 institutions in Japan from August 19, 2019, to September 30, 2020, with follow-up...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Carcinoma, Renal Cell

Share to HLA Antigens

Share to Immune Checkpoint Inhibitors

Share to Kidney Neoplasms

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 38758119
DOI: 10.4049/jimmunol.2300308
PMCID: PMC11212726

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.PMID 38758119Read ↗

Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.Semantic proximity Read ↗

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.Semantic proximity Read ↗

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced MelanomaSemantic proximity Read ↗

PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from All of Us cohortSemantic proximity Read ↗

Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC Study.Semantic proximity Read ↗

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.Semantic proximity Read ↗

Meta-analysis of the association between HLA-G 14-bp insertion/deletion polymorphism and susceptibility to viral infections and cancer risk.Semantic proximity Read ↗

Single-Nucleotide Polymorphisms (SNPs) Can Predict the Efficacy and Toxicity of Cancer Immunotherapy? A Systematic ReviewSemantic proximity Read ↗

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 AnalysisSemantic proximity Read ↗

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line therapySemantic proximity Read ↗

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 PolymorphismSemantic proximity Read ↗

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.